Results 41 to 50 of about 709,280 (306)

Pseudotype-based neutralization assays for influenza: a systematic analysis [PDF]

, 2015
The use of vaccination against the influenza virus remains the most effective method of mitigating the significant morbidity and mortality caused by this virus.
Ferrara, Francesca, Keith eGrehan, Temperton, Nigel J., George William Carnell, Craig Peter Thompson, Francesca eFerrara, Nigel James Temperton, Grehan, Keith, Carnell, George W., Thompson, Craig P., Francesca Ferrara, Keith Grehan   +11 more
core   +1 more source

Cattle develop neutralizing antibodies to rotavirus serotypes which could not be isolated from faeces of symptomatic calves [PDF]

, 1991
Neutralizing antibodies against 10 serotypes of rotavirus were measured in sera from different age groups of German cattle. Only five of 143 sera did not neutralize heterologous serotypes.
Sidoti, Josette, Eichhorn, Werner, Snodgrass, David, Büssow, Harald, Rohwedder, Angela   +4 more
core   +1 more source

Defining criteria for broadly neutralizing HIV antibodies

Frontiers in Immunology
Over the course of a few years, a small percentage of individuals with HIV-1 develop broadly neutralizing antibodies (bnAbs) capable of neutralizing diverse viruses.
Elizabeth-Sharon David-Fung, Katherine A. Belobrajdic, Jennifer P. Macke, Corey R. Quackenbush, Kumkum Ganguly, Jennifer L. Mamrosh   +5 more
doaj   +1 more source

Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. [PDF]

PLoS Pathogens, 2013
Identifying the targets of broadly neutralizing antibodies to HIV-1 and understanding how these antibodies develop remain important goals in the quest to rationally develop an HIV-1 vaccine.
Constantinos Kurt Wibmer, Jinal N Bhiman, Elin S Gray, Nancy Tumba, Salim S Abdool Karim, Carolyn Williamson, Lynn Morris, Penny L Moore   +7 more
doaj   +1 more source

Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco [PDF]

, 2014
The proposed clinical trial in Africa of VRC01, a potent broadly neutralizing antibody (bNAb) capable of neutralizing 91% of known HIV-1 isolates, raises concerns about testing a treatment which will be too expensive to be accessible by the most ...
Katja Klein, Julian K‐C. Ma, Klein, K, Ma, JK-C, Teh, AY, Ma, Julian K.C., Maresch, Daniel, Teh, AY-H, Klein, Katja, Ma, JK, Teh, Audrey Y.H., Audrey Y‐H. Teh, Daniel Maresch, Maresch, D   +13 more
core   +1 more source

Analysis of dengue specific memory B cells, neutralizing antibodies and binding antibodies in healthy adults from India

International Journal of Infectious Diseases, 2019
Background: The Indian population is facing highest dengue burden worldwide supporting an urgent need for vaccines. For vaccine introduction, evaluation and interpretation it is important to gain a critical understanding of immune memory induced by ...
Sivaram Gunisetty, Kaustuv Nayak, Ramesh Chandra Rai, Yadya Chawla, Elluri Seetharami Reddy, Charu Aggarwal, Deepti Maheshwari, Harekrushna Panda, Nasim Akhtar Ansari, Prabhat Singh, Manpreet Kaur, Kritika Dixit, Pragati Sharma, Priya Bhatnagar, Lalita Priyamvada, Siddhartha Kumar Bhaumik, Syed Fazil Ahamed, Rosario Vivek, Pratima Ray, Anita Shet, Poonam Coshic, Rakesh Lodha, Sushil Kumar Kabra, Dil Afroze, Adfar Yousuf, Rafi Ahmed, Kaja Murali-Krishna, Anmol Chandele   +27 more
doaj   +1 more source

Partial depletion of plasminogen activator inhibitor‐1 decreases subcutaneous fat cell hypertrophy and liver cholesterol in high‐fat‐fed female mice

FEBS Letters, EarlyView.
Obesity raises blood levels of PAI‐1, a protein linked to metabolic dysfunction‐associated steatotic liver disease in people with obesity. In female mice fed a high‐fat diet, partially lowering PAI‐1 led to smaller subcutaneous fat cells and lower liver cholesterol, without changing body weight or insulin sensitivity.
Claudia E. Ramirez Bustamante, Robert Sharp, Pradip K. Saha, Elizabeth S. Anaya, Elizabeth L. Lieu, Evelyn L. de Groot, Pooja Patel, Mi Jeong Heo, Aaron R. Cox, Kang Ho Kim, Sean M. Hartig   +10 more
wiley   +1 more source

A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls. [PDF]

PLoS ONE, 2013
The current generation of Human Papillomavirus (HPV) vaccines, Cervarix® and Gardasil®, exhibit a high degree of efficacy in clinical trials against the two high-risk (HR) genotypes represented in the vaccines (HPV16 and HPV18).
Eve Draper, Sara L Bissett, Rebecca Howell-Jones, Pauline Waight, Kate Soldan, Mark Jit, Nicholas Andrews, Elizabeth Miller, Simon Beddows   +8 more
doaj   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source